IPOs/Nasdaq Global Select Market/2026/Lycia Therapeutics, Inc.

Lycia Therapeutics, Inc. LYCA

Lycia Therapeutics, Inc. (LYCA) priced its IPO on Nasdaq Global Select Market on October 23, 2026 at $18.00 a share. Clinical-stage biotechnology company discovering and developing novel therapeutics to degrade disease-causing extracellular proteins, with initial focus on autoimmune, inflammatory and allergic diseases. Based in South San Francisco, California.

Registered
Priced
TradingNot yet
Offer price
$18.00
Raised
Not given
Shares offered
17,640,000 shares
Lock-up
180 days
See the prospectus →

The company

Lycia Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, discovering and developing novel therapeutics to degrade disease-causing extracellular proteins. It sold 17,640,000 shares at $18.00 per share.

The company will use the $290.7 million in net proceeds to advance clinical development of LCA-0061, LCA-0062 and LCA-0321 substantially through planned Phase 2 clinical trials, and for research pipeline, other R&D activities, working capital and general corporate purposes. Lycia Therapeutics, Inc. holds all shares after the offer.

Where the money goes

advance clinical development of LCA-0061 substantially through planned Phase 2 clinical trial
advance clinical development of LCA-0062 substantially through planned Phase 2 clinical trial
advance clinical development of LCA-0321 substantially through planned Phase 2 clinical trial
advance research pipeline, other R&D activities, working capital and general corporate purposes

Revenue and results

Revenue, six months ended June 30, 2026$—

The risks it lists first

Limited operating history, no completed clinical trials, no products approved for commercial sale
Significant operating losses since inception, no revenue from product sales, may never achieve profitability
Require substantial additional capital, may be forced to delay or eliminate programs